India has included 39 more drugs, under price control as part of its latest effort to make medicines affordable in the country, including the ones used to treat diabetes and digestive disorders.
As per the notification of National Pharmaceutical Pricing Authority (NPPA), the prices of formulations including Ciprofloxacin Hydrochloride, Cefotaxime, Paracetamol, Domperidone and Metformin+Glimepiride have been fixed.
The latest move of the government will include medicines made by pharmaceutical companies, including Cadila Healthcare, Lupin, IPCA Laboratories, Abbott Laboratories and GlaxoSmithKline.
The new drugs join a price control list that covers more than 500 drugs. In the month of May, NPPA had capped the prices of 30 formulation packs, including the drugs that treat tuberculosis, diabetes and asthma.
The move comes after a parliamentary committee said in April that the scope of price control needed to be expended.